SCHEMBL4407210

SCHEMBL4407210

CC(C)n1nnnc1-c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.65
POLB P06746 2/20 0.59
CYP2C19 P33261 2/20 0.59
CYP1A2 P05177 1/20 0.59
ALDH1A1 P00352 4/20 0.50
TSHR P16473 3/20 0.50
ALOX15 P16050 1/20 0.49
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.45
HTT P42858 1/20 0.45
LMNA P02545 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PTGS2 P35354 2/20 0.43
MCOLN2 Q8IZK6 1/20 0.42
MAP3K5 Q99683 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
PKM P14618 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8947138 0.81 KMT2A (0.49) TDP1POLBCYP2C19CYP1A2ALDH1A1
SCHEMBL13226000 0.80 CYP1A2 (0.54) TDP1POLBCYP2C19CYP1A2ALDH1A1
SCHEMBL20774158 0.80 CYP1A2 (0.54) TDP1POLBCYP2C19CYP1A2ALDH1A1
SCHEMBL12030605 0.77 TDP1 (0.47) TDP1POLBCYP2C19CYP1A2ALDH1A1
SCHEMBL8947258 0.75 MAPT (0.55) TDP1POLBALDH1A1TSHRMAPT
SCHEMBL10631252 0.74 ALDH1A1 (0.41) TDP1POLBCYP2C19CYP1A2ALDH1A1
SCHEMBL11150658 0.74 TDP1 (0.56) TDP1POLBCYP2C19CYP1A2ALDH1A1
SCHEMBL822762 0.74 SMN1; SMN2 (0.55) POLBALDH1A1TSHRALOX15KMT2A
SCHEMBL10635348 0.73 ALDH1A1 (0.43) TDP1POLBCYP2C19CYP1A2ALDH1A1
SCHEMBL4403632 0.73 CNR2 (0.60) POLBCYP2C19CYP1A2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 US disclosed
US-11873290-B2 2024-01-16 US disclosed
US-11839144-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2023-12-05 US disclosed
EP-4248973-A2 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-09-27 EP disclosed
EP-3877376-B1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2023-08-23 EP disclosed
WO-2021231615-A1 SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. (US) 2021-11-18 WO disclosed
US-11091464-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2021-08-17 US disclosed
US-20210217973-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues UNIV ARIZONA STATE (US) 2021-07-15 US disclosed
US-11011712-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-05-18 US disclosed
US-20180226593-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2018-08-09 US disclosed
US-9941479-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-10 US disclosed
EP-1859782-B1 Composition for coloring and/or lightening human hair comprising tetrazoles HENKEL AG & CO KGAA (DE) 2009-12-30 EP disclosed
EP-1859782-A1 Composition for coloring and/or lightening human hair comprising tetrazoles Henkel Kommanditgesellschaft auf Aktien (DE) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180226593-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues DPYD, DCTD, TYMP TDP1 213/4885POLB 179/4885CYP2C19 4706/4885
US-11011712-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues DPYD, DCTD, TYMP TDP1 213/4885POLB 179/4885CYP2C19 4706/4885
US-20210217973-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues DPYD, DCTD, TYMP TDP1 213/4885POLB 179/4885CYP2C19 4706/4885
US-11873290-B2 IL6, MUSK, IL6ST TDP1 161/4885POLB 1623/4885CYP2C19 2085/4885
US-11839144-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues DPYD, DCTD, TYMP TDP1 213/4885POLB 179/4885CYP2C19 4706/4885
US-11091464-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A TDP1 213/4885POLB 1519/4885CYP2C19 1713/4885
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A TDP1 213/4885POLB 1519/4885CYP2C19 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.